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Abstract
Background: HIV-1 Nef is a virulence factor that plays multiple roles during HIV replication. Recently, it has been described
that Nef intersects the CD40 signalling in macrophages, leading to modification in the pattern of secreted factors that
appear able to recruit, activate and render T lymphocytes susceptible to HIV infection. The engagement of CD40 by CD40L
induces the activation of different signalling cascades that require the recruitment of specific tumor necrosis factor
receptor-associated factors (i.e. TRAFs). We hypothesized that TRAFs might be involved in the rapid activation of NF-kB,
MAPKs and IRF-3 that were previously described in Nef-treated macrophages to induce the synthesis and secretion of
proinflammatory cytokines, chemokines and IFNb to activate STAT1, -2 and -3.
Methodology/Principal Findings: Searching for possible TRAF binding sites on Nef, we found a TRAF2 consensus binding
site in the AQEEEE sequence encompassing the conserved four-glutamate acidic cluster. Here we show that all the
signalling effects we observed in Nef treated macrophages depend on the integrity of the acidic cluster. In addition, Nef was
able to interact in vitro with TRAF2, but not TRAF6, and this interaction involved the acidic cluster. Finally silencing
experiments in THP-1 monocytic cells indicate that both TRAF2 and, surprisingly, TRAF6 are required for the Nef-induced
tyrosine phosphorylation of STAT1 and STAT2.
Conclusions: Results reported here revealed TRAF2 as a new possible cellular interactor of Nef and highlighted that in
monocytes/macrophages this viral protein is able to manipulate both the TRAF/NF-kB and TRAF/IRF-3 signalling axes,
thereby inducing the synthesis of proinflammatory cytokines and chemokines as well as IFNb.
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Introduction
Several lentiviruses have evolved to infect non-dividing tissue
macrophages. Some non-primate lentiviruses, such as caprine
arthritis and encephalitis virus (CAEV) and Maedi-Visna virus
exhibit a restricted tropism for monocytes/macrophages [1–3],
whereas feline, simian and human immunodeficiency viruses (FIV,
SIV and HIV, respectively) have acquired a wider tropism and an
expanded range of target cells, involving CD4
+ T lymphocytes
beside macrophages [4–7]. The infection of CD4
+ T cells accounts
for many aspects of the viral pathogenesis, even if the capacity of
lentiviruses to infect macrophages and other antigen-presenting
cells (APC) plays a determinant role in the establishment,
spreading and persistence of the infection. In case of HIV-1
infection, the selective sexual transmission of monocytotropic
CCR5-restricted viruses has been reported [8,9] indicating that
macrophage tropism may facilitate establishment of virus infection
in the newly infected host. The capacity of monocytes and
macrophages to migrate in organs and to survive in tissues makes
them potential conveyors of HIV-1 infection. Moreover, unlike T
cells, HIV-infected macrophages appear to be resistant to the
cytopathic effects of the virus and to the current antiretroviral
therapies [10], thus serving as a reservoir for persistent infection.
Lentiviruses, in general, and HIV-1, in particular, impair
macrophage functions and alter the cytokines and chemokines
production pattern, resulting in chronic infection, tissue damage
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  Koreaand recruitment of target cells in the site of primary infection. It
has been demonstrated that in infected macrophages Nef mediates
lymphocyte chemotaxis and activation through the synthesis and
the release of MIP-1a, MIP-1b and other soluble factors, thus
improving lymphocyte recruitment and activation at virus
replication sites [11,12]. It has also been shown that Nef is able
to regulate the expression of some inflammatory cytokines such as
IL-1b, IL-6, TNF-a and the production of IFNb in infected cells as
well as in uninfected macrophages treated with the viral protein
[13,14].
HIV-1 Nef is a small myristoylated, cytoplasmic, multifunction-
al protein (MW 27–34 kDa) that acts as an adaptor molecule
partially associated with the cell membrane [15]. Nef-defective
viruses lead to an attenuated clinical phenotype with reduced viral
load in mouse models, monkeys, and human disease [16–20]. In
addition, nef transgenic mice develop an AIDS-like disease [21]
suggesting a pathogenic role for this HIV-1 accessory factor.
Several functions are ascribed to the interaction between Nef and
cellular counterparts; some of them, such as CD4 and class I
MHC downregulation, are detected in both T lymphocytes and
monocytes/macrophages, whereas others are cell type specific. In
CD4
+ T cells Nef interacts with TCR chain, Lck and PAK kinases
and the molecular adapters LAT and Vav thereby inducing a pre-
activation state in infected T cells. On the other hand, the
molecular mechanisms that allow the activation of monocytes/
macrophages and the synthesis and release of inflammatory
cytokines are less well characterized, even if we and others
reported that in macrophages Nef is able to activate NF-kB
signalling pathways and that this activation is responsible for the
production of cytokines and for the increased infection of resting T
lymphocytes [12,14].
Here we report that signalling events required for the synthesis
and the release of inflammatory factors and IFNb in human
monocytic cells treated with myristoylated recombinant Nef
require the integrity of the so called Nef acidic cluster (AC) made
by a four-glutamate stretch located in the N-terminus arm of the
protein. Modelling analyses reveal that AQEEEE sequence
perfectly matches the consensus binding sequence for the TRAF2
adapter protein and it is also compatible with the binding to
TRAF6. Pull-down assays demonstrate the ability of Nef to form
complexes only with TRAF2, whereas specific RNA silencing
suggests the involvement of both TRAF2 and TRAF6.
Results
The Nef Acidic Cluster is a putative TRAF2 consensus
binding site
The comparison between HIV-1 Nef primary structure and
TRAF2 consensus binding sequence [22] reveals the presence of a
putative binding motif in the sequence A
64QEEEE
69 (numeration
according to SF2 HIV-1 allele) encompassing the Nef AC (Fig. 1A).
Modelling analysis performed using crystallographic data obtained
on TRAF2/4-1BB complex [22] shows that the stereochemistry of
Nef 64–69 sequence stretch is highly compatible with TRAF2
binding site. In particular, in the modelled complex, Nef Ala
64 is
positioned inside a hydrophobic cavity lined by TRAF2 residues
Phe
447 and Phe
456, Nef Glu
66 forms a hydrogen bond with
TRAF2 Ser
454, and Nef Glu
67 and Glu
69 form salt bridges with
TRAF2 Arg
393 and Arg
403, respectively. On the other hand, the
comparison between the reported TRAF6 consensus binding
sequence [23] and the A
64QEEEE
69 motif indicates that the two
sequences are superimposable except for Ala
64 (Fig. 1B). Never-
theless, modelling analysis performed using the crystallographic
data obtained on TRAF6/RANK complex [23] reveals that, even
if the interaction of Nef Ala
64 with TRAF6 Phe
471, Met
450 and
Tyr
473 residues is probably weaker than the interactions made by
the Pro residue of the consensus sequence, electrostatic interactions
involving Glu
67, Glu
68 and Glu
69 of Nef with Arg
392, Lys
469 and
Arg
466 of TRAF6, respectively, can stabilize the interaction
between Nef and TRAF6 (Fig. 1B). Therefore, we produced
myristoylated recombinant NefSF2 (myr
+ recNef) by substituting
E
66EEE
69 with four alanines (mutant 4EA) testing if AC mutation
impact the overall Nef structure. As reported in Fig. 2A, both
myristoylated wild type Nef and the 4EA mutant displayed similar
profiles in circular dichroism analysis, supporting that the overall
structure is maintained in the mutant protein. In addition, both
proteins equally well interacted with the Hck-SH3 domain, a well
conserved function mediated by the Nef proline rich region [24]
(Fig. 2B). We also assessed the ability of AC-mutated recNef to
enter MDMs. To this purpose, myr
+ recNef 4EA as well as myr
+
wt proteins were AlexaFluor 488 labelled. MDMs were, then,
incubated with the fluorescent proteins and analyzed by confocal
microscopy and cytofluorimetry. Confocal microscopy analysis
showed a superimposable punctuate intracytoplasmic pattern of wt
and 4EA mutant (Fig. 2C). Cytofluorimetric analysis revealed that
not only myr
+ 4EA recNef is internalized as the wt protein, but it
seems to be internalized even with a faster rate (Fig. 2D). As
negative controls we observed that recNef internalization was
abrogated at +4uC and that both a signalling inactive Nef mutant
(i.e. G2A, see [13] and later in this article) as well as an unrelated
protein (Ovalbumin-FITC) were internalized, but were unable to
induce STAT1 and STAT2 tyrosine phosphorylation (data not
shown). Collectively, these results indicate that the EEEERAAAA
mutation impairs neither the overall structure nor the ability of the
protein to be internalized by MDMs.
Nef AC is essential to induce NF-kB in MDMs
Based on the structural models as well as on previous results
showing that Nef is able to intersect the CD40 signalling [12] and to
trigger NF-kB, MAPKs and IRF-3 signalling pathways [13], we
evaluated the possible involvement of the AC domain in NF-kB
pathway. Both myr
+ wild type and 4EA recNef proteins were used
to stimulate primary human MDMs. As negative controls we used
recNef mutants lacking the myristoylation site (G2A) or the first 44
amino acids (N-term.) as we previously demonstrated that both did
not activate NF-kB,MAPKs and IRF-3 intreatedMDMs [13]. NF-
kB activation was evaluated by testing both serine phosphorylation
of the catalytic subunits of the IKK complex (namely IKKa and
IKKb) as well as degradation of the inhibitory factor IkB-a.A3 0 9
treatment of MDMs with myr
+ wt recNef induced the phosphor-
ylation of both IKKa and IKKb (Fig. 3A) and degradation of IkB-a
(Fig. 3B), whereas myr
+ 4EA recNef was unable to induce both the
activation of IKKs and the degradation of IkB-a. The lack of IkB-a
degradation was observed using two different batches of the 4EA
mutant (i.e. myr
+ recNef 4EA9 and 4EA0, Fig. 3B). These results
demonstrate that both Nef myristoylation and the AC are necessary
for the activation of NF-kB.
Proinflammatory cytokine induction requires the
integrity of Nef AC
Myr
+ recNef treatment of primary MDMs as well as infection of
MDMs with nef espressing HIV-1 pseudotypes induces the synthesis
and the release of several inflammatory cytokines and chemokines
(i.e. IL-1b, IL-6, TNFa, MIP-1a and MIP-1b) [11,14]. The
expression of all these factors is tightly regulated by the presence
in their promoter sequences of kB responsive elements [25–28].
Therefore, we checked if myr
+ 4EA recNef was able to induce the
synthesis of these cyto- and chemokines in MDMs as we already
TRAF2 Involvement in Nef-Induced Signalling in MDM
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with100 ng/mlofmyr
+ wt recNeforwithG2A, DN-termand myr
+
4EA recNef. Total mRNA was analyzed by RT-PCR using specific
primers for IL-1b, IL-6, TNFa, MIP-1a and MIP-1b. Results in
Table 1 show a marked inhibition of all these proinflammatory
cytokines and chemokines transcripts (ranging from 82% for
CCL4/MIP-1b to up to 99% for IL-6) using two different
preparations of the myr
+ 4EA recNef. Dose-response analysis
reveal that as low as 6.25 ng/ml of myr
+ wild type recNef was able
to induce both TNFa and IL-6 mRNAs whereas 4EA mutant was
unable to induce these mRNAs at all doses tested (Fig. 4). Using the
IKKs specific inhibitor BMS-345541 [29] we also demonstrated
that the Nef-induced TNFa and IL6 mRNA upregulation is
dependent on NF-kB activation (Figure S1).
IRF-3 activation and IFNb production is dependent on
Nef AC
We previously reported that the myr
+ recNef treatment of
primary human MDMs induces the activation of the IRF-3
transcription factor that in turn allows the synthesis and release of
IFNb [13]. Several receptors induce type I IFNs using as signalling
intermediates TRAF family members e.g. the TLR4 and TLR3
members of the Toll Like Receptor family [30–32]. Therefore, we
supposed that the putative TRAF2 and/or TRAF6 binding motif
could be involved also in the Nef-induced IRF-3 activation and in
the IFNb production. To test this hypothesis primary MDMs were
treated with myr
+ wt as well as with myr
+ 4EA recNef, evaluating
the phosphorylation status IRF-3 as shift in the electrophoretic
migration of the protein. As shown in Fig. 5A, treatment of MDMs
with the wt protein induced the accumulation of a slower
migrating hyperphosphorylated form of IRF-3 with the concom-
itant disappearance of the faster migrating one. Conversely,
treatment with the myr
+ 4EA, the G2A, and the DN-term protein
was unable to activate IRF-3. We also tested the induction of the
mRNA coding for IFNb and the release of this cytokine in the
supernatant of Nef-treated MDMs, testing the antiviral activity.
Again, myr
+ 4EA recNef did not upregulate IFNb mRNA (Fig 5B)
and failed the release of IFNb at all doses we tested (Fig. 5C). A
Figure 1. Putative complexes formed by Nef Acidic Cluster with TRAF2 and TRAF6. Upper panels: sequence alignment between Nef AC
and TRAF2 (A) or TRAF6 (B) binding sites in known TRAF interactors. The conserved residues within the consensus sequence are in black background
whereas the residues present in Nef AC as well as in TRAF2 and TRAF6 interactors are in gray background. Mismatched Ala in Nef compared to TRAF6
consensus in (B) is in gray. TRAFs interactors sequences are as in [22,23]. Lower panels: schematic representation of the modelled complexes formed
by Nef AC with TRAF2 (A) and TRAF6 (B). Nef AC-TRAF2 complex has been modelled using the three-dimensional structure of the TRAF2/4-1BB
complex (PDB code: 1D0J) [22] as a template. Nef AC backbone is shown in green, TRAF2 backbone in gold. Nef AC-TRAF6 complex has been
modelled using the three-dimensional structure of the TRAF6/RANK complex (PDB code 1LB5) [23]. Nef AC backbone is shown in green, TRAF6
backbone in magenta.
doi:10.1371/journal.pone.0022982.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22982Figure 2. Acidic Cluster Nef mutant characterization. (A) Circular dichroism spectroscopy analysis of myr
+ wild type recNef protein (black line)
and myr
+ 4EA recNef mutant (red line) revealed similar secondary structure content from both proteins. (B) GST-HCKSH3 pull down assays with
recombinant Nef protein showed binding to both wild type Nef and the 4EA mutant in a comparable manner (lanes 7–9), supporting the structural
integrity of the protein. For input control, recNef proteins were similarly incubated alone (lanes 1–3) or in presence of GST beads (lanes 4–6). (C, D)
Wild type Nef and 4EA mutants are internalized by MDMs. Cells were treated with 300 ng/ml of the corresponding recombinant proteins labelled
with AlexaFluor488 green dye. For CM (C), MDMs were cultured on glass bottom dishes and treated for 309 wt or 4EA myr
+ recNefSF2-Alexa488, then
counterstained with PKH26 red fluorescent dye, fixed and analysed. Left panels: merged images of stained cells. Right panels: Differential Interference
Contrast (DIC) images. (D) For CFM analysis cells were treated for the indicated times with wild type (left panel) or 4EA (right panel) recNef proteins.
Gray plot: untreated cells; sky blue: 309: light blue: 2 h; blue: 6 h; dark blue 24 h.
doi:10.1371/journal.pone.0022982.g002
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+ wild type recNef induced the
release of IFNb. These results demonstrate that the AC is required
also for synthesis and release of IFNb.
Both myristoylation and AC are essential to induce the
tyrosine phosphorylation of STAT1, STAT2 and STAT3
The release of the inflammatory cyto- and chemokines and
IFNb induces in MDMs a second wave of activation through the
JAK/STAT signalling pathway. In particular, tyrosine phosphor-
ylation of STAT1, STAT2 and STAT3 was observed [13,33,34].
Based on the above-reported results it is plausible to suppose that
myr
+ 4EA recNef was unable to induce the activation of these
signal transducers and activator of transcription. As expected,
myr
+ 4EA, G2A, DN-term recNef were unable to induce the
tyrosine phosphorylation of STAT1, -2 and -3 in primary MDMs
(Fig. 6). Again, we observed the lack of STATs tyrosine
phosphorylation using two different 4EA mutant preparations.
These results indicate that the E
66EEE
69 motif is also essential for
the induction of this second JAK/STAT-based wave of regulation.
The AC mutation markedly reduces in vitro interaction of
wt Nef with TRAF2
As reported in the first paragraph and in Fig. 1, Nef AC is part
of a consensus binding sequence for TRAF2 and fits with the
TRAF6 binding surface. To test if Nef and TRAFs could
physically interact in vitro, both wt and 4EA Nef-GST fusion
proteins were produced and used in pull down assays. As depicted
in Fig. 7, wt Nef-GST was able to pull down TRAF2, whereas a
statistically significant reduction in this interaction was detectable
using the 4EA Nef-GST preparation (p.0.05 using ANOVA test).
The 4EA mutant still retain the ability to bind Hck at comparable
levels to wt Nef (Fig. 7, middle panel and Fig. 2B), thereby
demonstrating that the AC mutation does not affect the overall
Nef binding ability with other known interactors. As negative
control, GST alone was unable to bind any TRAF2. Neither wt
nor 4EA Nef-GSTs were able to pull down TRAF6 (data not
shown) indicating that, at least in vitro, this interaction was not
detectable. We also tried to perform in vivo Nef-TRAF2 and Nef-
TRAF6 co-immunoprecipitation assay on Nef-treated MDMs in a
time course experiment (59 to 309) but we didn’t record any signals
because the amount of recNef internalized by MDMs is probably
too low to allow detection by Western Blot (data not shown).
Silencing of both TRAF2 and TRAF6 inhibits the
Nef-induced STATs tyrosine phosphorylation
The above described experiments didn’t formally demonstrate
the involvement of TRAF family members in signalling effects
induced by Nef in MDMs. To confirm the involvement of TRAF2
and/or TRAF6 in these events, silencing experiments were
performed on the human monocytic cell line THP-1. Indeed,
recNef treatment induces in these cells signalling effects superim-
posable to those observed in primary human MDMs (G. Mangino,
unpublished data). THP-1 cells were transfected with TRAF2 or
TRAF6 specific siRNA pools. Seventy-two hours later, cells were
treated with myr
+ wt recNef for 6 h. As shown in Fig. 8, recNef
induced only a very light STAT1 and STAT2 tyrosine
phosphorylation signal in TRAF2 silenced cultures. Surprisingly
enough, a similar result was obtained even in TRAF6 silenced
cultures. As a negative control, THP-1 cells silenced with
unrelated siRNA (i.e. HPV16 E7 siRNA) responded to myr
+
recNef treatment as well as control cultures. Therefore both
TRAF2 and TRAF6 appear to be involved in the cytokines-
mediated activation of STAT1 and STAT2.
Discussion
Emerging evidences point out the ability of the HIV-1 Nef
protein to hijack cellular signalling pathways to promote viral
replication and spreading. Nef affects the function of macrophages
inducing the production of two CC-chemokines, (i.e. CCL3/MIP-
1 and CCL4/MIP-1b) possibly to recruit CD4
+ T cells at the sites
of virus replication, and induces the release of soluble factors from
macrophages (i.e. sICAM-1 and sCD23) stimulating B cells to
Figure 3. Nef induces NF-kB signalling in an Acidic Cluster
dependent manner. Seven days old human primary MDMs were
treated for 309 with 100 ng/ml of myr
+ wild type (WT) recNef, the
protein lacking the first 44 aminoacids (DN-Term), mutated in the
myristoylation site (G2A) or myr
+ recNef 4EA mutant. Total cell protein
extracts (50 mg) were analyzed by Western Blot as reported in Materials
and Methods section using specific anti phospho-IKKa/IKKb and anti
IKKa/IKKb (A) or with anti IkB-a (B) antibodies. In both (A) and (B) b-
tubulin steady-steate expression level was used as an internal loading
control. Results shown represent one out three different donors.
doi:10.1371/journal.pone.0022982.g003
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and replication [11,12]. These findings suggest that Nef influences
the activation status of the infected cells to generate a suitable
environment for virus production also increasing the susceptibility
of the surrounding cellular reservoir to infection. Recent
observations also indicate a role of Nef to interfere with signalling
events in uninfected cells that are able to pick it up from the
extracellular milieu or by cell to cell transfer [35–37].We have
already reported that exogenously added Nef induces on in vitro
cultured MDMs the synthesis and the release of proinflammatory
cytokines and chemokines and IFNb in a NF-kB dependent
manner. After 1.5/2 h of cell treatments with the viral protein the
pool of secreted factors are able to activate STAT1, STAT2 and
STAT3 in an autocrine and paracrine manner [13,14,33,34].
Nevertheless the molecular mechanisms involved in these
phenomena as well as the Nef structural domains involved in
these activations remained elusive. Results reported here clearly
indicate that beside the myristoylation site, already identified as an
essential hallmark to achieve NF-kB, IRF-3 and STATs
activations, the other main structural domain involved in these
functions is the N-terminal acidic cluster E
66EEE
69. Fig. 3 shows
that Glu to Ala substitutions within the AC in the myr
+ 4EA
mutant completely abrogate the ability of Nef to induce IKKs
phosphorylation and IkB degradation, thereby preventing the
activation of NF-kB signalling events. Due to the strict
interdependence between the activation of the canonical NF-kB
pathway and all the downstream events, the overall effect of this
Nef mutation is the lack of induction of proinflammatory state,
attested by the unsuccessful induction of specific cytokines and
chemokines mRNA, as well as the lack of the subsequent STATs
tyrosine phosphorylation (see Table 1 and Figs. 4 and 6). In
addition, results shown in Fig. 5A demonstrate that the 4EA
mutation, affecting the Nef-induced IRF-3 phosphorylation, also
prevents the synthesis and the release of IFNb (Fig. 5B and 5C).
We obtain these results by treating cells with 100 ng/ml recNef
except for confocal microscopy analysis and silencing experiments
in which 300 and 200 ng/ml respectively were used. In particular,
in the silencing experiments we used THP-1 cells that are not
differentiated macrophages and display a reduced uptake ability
compared to MDMs. The used quantities are 10 to 30-fold higher
to the amount of Nef found in the sera of HIV-1 infected
individuals [38]. Nevertheless it has been speculated that this
concentration might be even higher in the lymphonodal germinal
centers, where virion-trapping dendritic cells, virion-infected
CD4
+ T cells and macrophages are densely packed [39]. In
addition, the results shown in Figs. 4 and 5C demonstrate the
induction of pro-inflammatory cytokines and IFNb at doses as low
as 6,25 ng/ml close to those recorded in the patients sera. These
events require NF-kB activation and are mandatory for the
subsequent STATs tyrosine phosphorylation.
Previous studies identified the AC as the domain mainly
involved in the Nef-dependent downregulation of HLA-A and -B
alleles [40]. Analyses performed on primary Nef structure
evidenced the great conservation of this domain along Nef
sequences derived from different HIV-1 laboratory adapted strains
as well as primary isolates [41,42]. In addition, we found a TRAF2
consensus binding site in the AQEEEE sequence encompassing the
conserved four-glutamate acidic cluster. Even if some divergences
from the TRAF2 consensus binding sequence were reported, it is
noteworthy that they never affect the Glu
69. Indeed, only a
conservative Glu to Asp substitution was found in 2 out of 50
sequences recorded. In addition, just a Glu to Ser substitution was
reported for Glu
67 beside some conservative Glu to Asp
substitutions (i.e. 15 out of 50 sequences) [42]. Glu
66 was found
to be substituted by Gln in 4 out of 50 sequences, thereby
preserving the TRAF2 consensus sequence, whereas only a
Glu
66RLys substitution was reported in a rapid progressor patient
[42]. Further, just 1 out of 50 sequences showed a substitution in
the Ala
64 (i.e. from Ala to Arg) and this mutation characterizes the
isolate from a non-progressor patient [42]. The structural models
that we elaborated suggest that both Glu
67 and Glu
69 represent,
indeed, key residues for the interaction with both TRAF2 and
TRAF6 within the AC. Recently, Baugh and colleagues have
reported that mutants containing one or both Glu
67 and Glu
69
mutated to Ala still retain the ability to downregulate HLA-A and -
B alleles as well as to induce the activation of Pak-2 serine kinase
[43]. These results indicate that the selective pressure imposing the
conservation of an acidic residue in these two positions is not based
on these functions, but it rather resides in other functions mediated
by Nef. TRAFs silencing experiments (Fig. 8) suggest that the
ability of the viral protein to activate the synthesis and the release
of proinflammatory factors and IFNb through TRAF2 and
TRAF6 could be one of these functions.
As mentioned above, Swingler and colleagues describe that
HIV-1 Nef intersects CD40 signalling in monocytes/macrophages
thereby promoting the recruitment and infection of resting T cells
[12]. It has been shown that CD40 transduces its activation signals
engaging at least three different TNF receptor associated factors
(i.e. TRAF2, -3 and -6) [44–48]. It has also been reported that
TRAF2 is able to recruit the IKK complex through a direct
interaction with the leucine zipper motifs of both IKK and IKKb
[49]. Pull down assay (Fig. 7) and TRAF2 RNA interference
Table 1. RT-PCR analysis of cytokines and chemokines induced in MDMs following recNef treatment.
MDM Treatment (2 h)
n-Fold Induction*
(% of Inhibition**)
IL-1b IL-6 TNF-a CCL3/MIP-1a CCL4/MIP-1b
None 1 1111
wt recNefSF2 357.05 7486.11 249.00 324.03 303.38
G2A recNefSF2 1.80 (99.49) 6.92 (99.9) 3.31 (98.67) 1.77 (99.45) 9.13 (96.99)
DN-Term recNefSF2 9.92 (97.22) 83.58 (98.88) 11.20 (95.5) 6.70 (97.93) 18.96 (93.75)
4EA9 recNefSF2 6.82 (98.09) 39.95 (99.46) 9.06 (96.36) 6.23 (98.08) 16.11 (94.69)
4EA0 recNefSF2 36.50 (89.78) 487.75 (93.48) 27.57 (88,93) 23.18 (92.85) 52.71 (82.62)
*Expressed using as reference the value obtained in untreated cells.
**Calculated considering as reference the value obtained in MDMs treated with wt Nef.
doi:10.1371/journal.pone.0022982.t001
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22982Figure 4. Dose-response analysis of IL-6 and TNFa mRNA. Primary human MDMs were treated for 2 h with the indicted doses of myr
+ wild
type recNef (dark line, empty circles) or myr
+ 4EA recNef mutant (gray line, empty squares). Cells were processed as reported in the Materials and
Methods section. Upper panel: IL-6 mRNA levels; lower panel: TNFa mRNA levels. Results in figure and in Table I represent two out of four
independent experiments.
doi:10.1371/journal.pone.0022982.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22982experiments (Fig. 8) suggest that Nef intersect CD40 signalling by
a direct interaction with TRAF2 and subsequent recruitment and
activation of IKK complex. The results reported here underline
that this interaction involves the Nef AC. It is interesting to note
that all the members of the TNF receptor family, including CD40,
require trimerization to start signalling events and that Nef has
also the tendency to make both dimers and trimers but not higher
oligomers [50], opening the possibility that Nef needs to trimerize
Figure 6. Tyrosine phosphorylation of STAT1, STAT2 and
STAT3 requires the Nef Acidic Cluster. MDMs were treated for 2 h
with 100 ng/ml of myr
+ wt as well as with DN-Term, G2A or myr
+ 4EA
recNef. Total cell protein extracts (50 mg) were analyzed by Western Blot
using specific anti phosphotyrosine-STAT1, anti phosphotyrosine-STAT2
and anti phosphotyrosine-STAT3 antibodies. Steady-state expression
levels of STAT1, STAT2 and STAT3 were evaluated using corresponding
specific antibodies whereas b-tubulin steady-steate expression level
was used as an internal loading control. Results were obtained from
four independent healthy donors.
doi:10.1371/journal.pone.0022982.g006
Figure 7. Nef interacts in vitro with TRAF2. Recombinant GST-Nef
proteins (WT or 4EA mutants) were incubated with THP-1 total cellular
lysates. Pull-down assay was performed as reported in Materials and
Methods section and samples were analyzed on 9% SDS-PAGE. Western
Blot was performed using anti-TRAF2 (Upper panel) or anti-Hck (Middle
panel) specific antibodies. As gel loading control, samples were
analyzed on SDS-PAGE and proteins were detected by Ponceau S
staining (Lower panel). Band intensities were quantified using ImageJ
v1.32J and data were normalizing using Hck signals as calibrator. Mean
intensity as well as standard deviation was calculated using data
collected from three independent experiments and statistical analysis
performed using InStat3 and ANOVA test.
doi:10.1371/journal.pone.0022982.g007
Figure 5. Nef-dependent activation of IRF-3 and synthesis of IFNb requires the integrity of the Acidic Cluster. (A) MDMs were treated
with myr
+ wt as well as with DN-Term, G2A or myr
+ 4EA recNef (100 ng/ml for 309). Total cell protein extracts (30 mg) were analyzed by Western Blot
using anti-IRF3 specific antibodies. IRF-3 activation was visualized as accumulation of the slower migrating form of the protein corresponding to the
iperphosphorylated form and the decrease of the faster migrating band. b-tubulin steady-steate expression level was used as an internal loading
control. (B) MDMs were treated for 2 h with myr
+ wt as well as with DN-Term, G2A or myr
+ 4EA recNef (100 ng/ml, 2 h). Cell were processed, total
RNA was isolated and Real Time PCR was performed as described in Material and Methods section. Results are expressed as fold of induction using
the levels of IFNb mRNA expression in untreated cells as reference. (C) Supernatants collected from MDMs treated for 2 h with twofold dilution of
myr
+ wt (black line, empty circles), 4EA (gray line, empty squares) or 100 ng/ml of heat-inactivated myr
+ wt recNef (black triangle), were tested for the
induction of the antiviral state on A549 indicator cells. Results are expressed as International Units (IU) of IFN/ ml. Results were obtained from four
independent healthy donors.
doi:10.1371/journal.pone.0022982.g005
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our hands Nef was unable to interact in vitro with TRAF6 in pull
down experiments (data not shown). Nevertheless, silencing
experiments using specific TRAF6 siRNA indicate that also this
adapter could be involved in the signalling events leading to the
synthesis and the release of STAT1 and -2 activating factors.
CD40 recruits TRAF6 through a direct interaction, thereby
initiating a signalling cascade leading to activation of NF-kB and
MAPKs [44,51], whereas other receptors attract it through other
adaptors such as MyD88 or IRAK-1 [52,53]. The lack of any
TRAF6 specific signal in pull down assays that we performed using
Nef-GST fusion proteins could be due either to an indirect
interaction between Nef and TRAF6 mediated by other molecules
or to a weak direct interaction between these proteins that could
not be detected by pull-down techniques.
It is noteworthy that other viruses evolved the ability to interact
and/or interfere with TRAFs functions through a particular viral
product. This is, indeed, the case of EBV LMP-1, HHV-8 K15,
herpesvirus Saimiri STP-A and HCV NS5A [54–57]. We propose
that Nef belongs to such a family of ‘‘viral hijackers’’ thus leading
to the induction of the inflammatory state in MDMs by subduing
TRAFs mediated signalling events to viral replication purposes.
Materials and Methods
Cells, recombinant Nef preparations and reagents
Peripheral Blood Mononuclear Cells (PBMCs) were isolated
from buffy coats obtained from healthy donors at Centro
Trasfusionale-Cattedra di Ematologia, Universita ` degli Studi
‘‘La Sapienza’’ Rome. No ethical approval from our and
university ‘‘La Sapienza’’ ethics committees nor formal or verbal
informed consent from blood donors were necessary to use buffy
coats as sources of primary monocytes. Cells were isolated by
positive selection using CD14 microbeads and LS columns, all
purchased from Miltenyi Biotech (Auburn, CA), following the
manufacturer’s recommendations. The purity of the recovered cell
populations was assayed by cytofluorimetric analysis by means of
phycoerythrin-conjugated anti-CD14 monoclonal antibody (clone
UCHM-1, Chemicon-Cymbus, Temecula, CA) labelling. Cell
preparations staining below 95% positive for CD14 (a cell surface
marker specific for monocyte/macrophage cell populations) were
discarded. Seven-day-old MDMs were obtained, as previously
described [13], by culturing monocytes for the first 3 days in
RPMI 1640 supplemented with 20% heat-inactivated fetal calf
serum (FCSi) (both from Lonza, Milan) and 50 ng/ml of
granulocyte-macrophage colony-stimulating factor (a kind gift
from Schering-Plough, Milan, Italy), to promote macrophage
differentiation, and for the last 4 days in the same medium without
granulocyte-macrophage colony-stimulating factor. THP-1 cell
line, derived from an acute monocytic leukemia [58], was grown in
RPMI 1640 supplemented with 10% FCSi. A549 cell line, derived
from a human lung carcinoma [59], was grown in Dulbecco’s
modified minimal essential medium supplemented with 10%
FCSi. Wild type myristoylated NefSF2, a mutant in the acidic
cluster (E
66EEE
69RAAAA), a mutant lacking the first 44 amino
acids (N-term) and a myristoylation deficient mutant (G2A), were
co-expressed with a N-myristoyl-transferase expression vector in
E.coli induced in presence of myristic acid and purified as C-
terminal hexahistidine-tagged fusion proteins as previously
described [60]. Wild type as well as 4EA mutant preparations
were checked by SDS-PAGE and Coomassie staining after
purification (see Fig. S2). Nef preparations were analyzed for the
presence of endotoxin using the chromogenic Limulus amebocyte
lysate endpoint assay QCL-1000 and, if required, purified using
the EndoTrap endotoxin removal system (both from Lonza). To
avoid possible signalling effects due to residual lipopolysaccharide
(LPS) traces in Nef preparations, all of the experiments were
performed in the presence of 1 mg/ml of polymyxin B (Sigma-
Aldrich, Milan, Italy), a cationic antibiotic that binds to the lipid A
portion of bacterial LPS. In our hands, this polymyxin B treatment
did not interfere with the signalling events analyzed and blocked
the signalling activity of up to 50 endotoxin units (EU)/ml LPS.
Circular Dichroism Spectroscopy
CD spectra were recorded on a Jasco J-815 spectropolarimeter
at 25uC using a quartz cuvette with a path length of 1 mm. The
myristoylated Nef proteins were dialyzed against 5 mM KPi buffer
(pH 8.2) and measured at a concentration of 5.0 mM. Spectra
were recorded with a step size of 1 nm and an integration time of
1 s. The raw CD signal (in millidegrees), after subtraction of the
blank signal of the cuvette and buffer, was converted to mean
residue ellipticity (in degrees squared centimeters per decimole)
similarly as described [59].
Plasmids, constructs and GST fusion proteins
The plasmid expressing Nef acidic domain mutant, designated
as pCDNA3-Nef 4EA, was obtained from vector expressing wild
type Nef derived from NL4-3 Nef allele, by replacing Glu
62 to
Glu
65 codons (corresponding to Glu
66 to Glu
69 in the SF2 allele)
by alanines, using Stratagene QuickChange II site-directed
mutagenesis kit (M-Medical, Milan, Italy) according to the
manufacturer’s instructions with minor modifications. In particu-
lar, we extended the PCR cycles to 25, we purifed PCR products
Figure 8. Both TRAF2 and TRAF6 silencing interfere with Nef-
induced STAT1 and STAT2 tyrosine phosphorylation. THP-1
cells were transfected with specific TRAF2, TRAF6 or unrelated (i.e. for
HPV16 E7) siRNA as described in Material and Methods section. Cells
were then incubated with recNef (200 ng/ml) for 6 h. Total cell protein
extracts (50 mg) were analyzed by 7% SDS-PAGE and Western Blot was
performed using specific anti phosphotyrosine-STAT1 and anti phos-
photyrosine-STAT2 antibodies. STAT1 and STAT2 steady-state expres-
sion levels were checked using the corresponding specific antibodies.
Anti-TRAF2 and anti-TRAF6 antibodies were used to verify the
specificity of silencing, ruling out off-target effects. b-tubulin steady-
state expression level was used as an internal loading control. Results
reported in figure represent one out of three independent silencing
experiments.
doi:10.1371/journal.pone.0022982.g008
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system (Promega, Milan, Italy) and we transformed DH5 E. coli
strain by electroporation with the purified PCR product. The
following primers were used for the PCR reaction:
4EA Forward 59-(p)cctggctagaagcacaagcggcggcagcggtgggttttcc-39;
4EA Reverse 59-(p)ggaaaacccaccgctgccgccgcttgtgcttctagccagg-39.
The mutant sequence was verified by DNA sequencing. Wild
type Nef and mutated Nef 4EA were next introduced into
pGEX6P3 (GE Healthcare, Milan, Italy) in two steps: initially the
ORFs were subcloned into pET-28a(+) (Novagen/Merck, Darm-
stadt, Germany) using Hind III/Not I sites. Next, the ORF
codifying Nef wt and Nef 4EA were excised from pET-28a(+)
using the Bam HI site (59 to Hind III), available in the pET-28a(+)
multiple cloning region, and introduced into pGEX6P3 using Bam
HI/Not I sites. Details of each construct are available upon
request. All ligation reactions were performed using Quick Ligase
(New England Biolabs, Ipswich, MA), according to the manufac-
turer’s instructions.
Western blot assay
MDMs were washed twice with phosphate-buffered saline
(PBS), pH 7.4, and lysed in 20 mM HEPES, pH 7.9, 50 mM
NaCl, 10 mM EDTA, 2 mM EGTA, 0.5% nonionic detergent
IGEPAL CA-630 (Sigma-Aldrich), 0.5 mM dithiothreitol (DTT),
20 mM sodium molybdate, 10 mM sodium orthovanadate,
100 mM sodium fluoride, 10 mg/ml leupeptin, 0.5 mM phenyl-
methylsulfonyl fluoride for 209 in ice. Whole-cell lysates were
centrifuged at 6,000 g for 109 at 4uC, and the supernatants were
frozen at 80uC. The protein concentrations of cell extracts were
determined by the Lowry protein assay. Aliquots of cell extracts
containing 20 to 50 mg of total proteins were resolved on 7 to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred by electroblotting them on nitrocellulose
membranes (Sartorius, Gottingen, Germany) overnight at 30 V
with a Bio-Rad Trans-Blot apparatus. For the immunoassays,
membranes were blocked in 3% bovine serum albumin (BSA)
fraction V (Sigma-Aldrich, Milan, Italy) in TTBS/EDTA (10 mM
Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% Tween 20) for
1 h at RT and then incubated for 1 h at RT or overnight at +4uC
with specific antibodies diluted in 1% BSA/TTBS-EDTA.
Antibodies used in the different immunoblottings were as follows:
rabbit polyclonal antibodies anti-phospho-IKKa(Ser180)/IKKb(-
Ser181), anti-IKKa, anti-IKKb, anti-IkB-a, anti-phospho-Stat1(-
Tyr701), anti-phospho-Stat3(Tyr705), all from Cell Signaling
Technology (Beverly, MA); rabbit polyclonal antibodies anti-
STAT1 (E-23), anti-STAT2 (C-20), anti-STAT3 (C-20), anti-IRF-
3 (FL-425), anti-Hck (M-28), anti-TRAF2 (C-20) and anti-TRAF6
(H-274) all from Santa Cruz Biotechnology (Santa Cruz, CA);
mouse monoclonal anti b-tubulin from ICN Biomedicals (Costa
Mesa, CA); rabbit polyclonal anti-phospho-STAT2(Tyr689) from
Upstate Biotechnology/Millipore (Billerica, MA). Immune com-
plexes were detected with horseradish peroxidise conjugated goat
anti-rabbit or goat anti-mouse antiserum (Calbiochem), followed
by enhanced chemiluminescence reaction (ECL; Amersham
Pharmacia Biotech, Milan, Italy). To reprobe membranes with
antibodies having different specificities, nitrocellulose membranes
were stripped for 59 at RT with Restore Western Blot Stripping
Buffer (Pierce, Rockford, IL) and then extensively washed with
TTBS/EDTA.
Pull-Down Assays
GST-HckSH3 pull down assay with Nef protein were prepared
in 10 mM Tris buffer, pH 8.0, and subjected to SDS PAGE
analysis, similarly as described [58]. For TRAF2/GST-Nef pull
down assay, GST-Nef wt or GST-Nef 4EA fusion proteins were
expressed and purified according to the described procedure [61].
For pull down experiments, THP-1 cells were lysed in pull-down
buffer (20 mM Hepes pH 7.5, 50 mM NaCl, 10% Glicerol,
10 mM EDTA, 2 mM EGTA, 0,5% Igepal CA-630, 1 mM
Na3VO4, 10 mM Na2MoO4, 0,5 mM PMSF, 2 mg/ml Aproti-
nin, 2 mg/ml Leupeptin, all from Sigma-Aldrich). Next 40 mgo f
GST-fusion proteins immobilized onto GSH beads were incubat-
ed with 2 mg of total cellular lysate for 3 hours at 4uC in a pull-
down buffer. Specifically bound proteins were resolved on an
SDS-PAGE (9%) and transferred overnight onto nitrocellulose
membranes. GST and GST-Nef were detected by Ponceau S
staining. Membranes were then blocked in TBS buffer containing
BSA (3%) for 1 h and then incubated overnight with anti-TRAF2
or anti-Hck antibodies, followed by detection with horseradish
peroxidase-conjugated anti-rabbit IgG and the ECL.
RNA isolation and real-time PCR
Real-time PCR assays were performed on total RNA isolated
from MDMs treated or not for 2 h with 100 ng/ml of
recombinant Nef or its mutants, using the RNeasy mini kit
(Qiagen, Milan) according to the manufacturer’s instructions. Five
hundred nanograms of total RNA was reverse transcribed using
oligo(dT)12–18 (Pharmacia-Biotech) as a primer and 50 units of
Moloney murine leukemia virus reverse transcriptase enzyme
(Gibco/Invitrogen, Milan). Quantitative real-time PCR was then
performed on reverse-transcribed IFNb, IL-1b, IL-6, TNF-a,
CCL3/MIP-1a and CCL4/MIP-1b mRNAs. The expression of
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to
normalize the mRNAs levels. Basal mRNA level observed in
untreated cells, was chosen as a calibrator. Oligonucleotides used
in the RT-PCR are reported in Table 2.
Antiviral assay
The antiviral activities of supernatants collected from Nef-
treated MDMs were tested on A549 cells. A 96-well microtiter
plate (Greiner bio-one, Frickenhausen, Germany) was seeded with
4610
4 A549 cells/well in Dulbecco’s modified minimal essential
medium, 2% FCSi. After 24 h, the culture medium was replaced
with twofold dilutions of Nef-treated MDM conditioned medium
(100 mL). Twenty-four hours later, cell cultures were infected with
100 ml of a 1:1,000 dilution of murine encephalomyocarditis virus
(EMC viral titer: 2.8610
8 PFU/ml) and incubated for an
additional 24 to 48 h. The cytopathic effect was visualized under
inverted microscopy, and antiviral activity was calculated using a
preparation of recombinant IFNb (Rebif; 9610
7 IU/ml,
3610
8 IU/mg of protein; Ares-Serono) as a standard.
Nef labelling, cytofluorimetric (CFM) assay and confocal
microscopy (CM)
One hundred micrograms of wild type and 4EA myr
+ recNefSF2
was labelled using AlexaFluor488 Microscale Protein Labelling
Kit (Molecular Probes/Invitrogen, Italy) following the manufac-
turer’s recommendations. The labelled protein concentration and
the degree of labelling (DOL) were determined by spectrophoto-
metric methods. The DOL of wild type and 4EA myr
+ recNefSF2-
Alexa-488 conjugated preparations ranging from 2.42 and 2.68
moles dye/mole protein and the conjugated protein concentra-
tions were 275 and 153 mg/ml, respectively. For CFM analysis,
cells were treated with myr
+ recNefSF2-Alexa488 (300 ng/ml),
then washed twice with phosphate-buffered saline pH 7.4 (PBS)
2% FBS, harvested and fixed in PBS 2% paraformaldehyde for
609 on ice. Afterwards, cells were washed once with PBS and CFM
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25 mW, on FL1 channel, pass-band filter to 520 nm). Fluorescence
analyses were performed using the FLOMAX- v.2.4b software. For
CM, MDMs were cultured on glass bottom dishes (MatTek
Corporation, Ashland, MA) and treated for 309 with 300 ng/ml
wt or 4EA myr
+ recNefSF2-Alexa488, then fixed in PBS 2%
paraformaldehyde for 609 on ice, washed four times with PBS and
analysed using confocal microscope (Leica TCS SP5). Plasma
membranecounterstaining was performedby treating MDMsfor59
with PKH26-GL using PKH26 Red Fluorescent Cell Linker Kit for
General Cell Membrane Labeling (Sigma-Aldrich) following the
manufacturer’s recommendations before fixing the cells.
THP-1 transfection, TRAF2 and TRAF6 silencing
Silencing experiments were performed using TRAF2 and
TRAF6 specific SMARTpool siRNA and DharmaFECT 2
reagent (both from Dharmacon/Thermo Fisher Scientific, Lafay-
ette, CO). As negative control a HPV16 E7 specific siRNA was
used. In particular THP-1 cells were resuspended in Optimem
reduced-serum medium (Gibco/Invitrogen) and seeded at 2610
5
cells/ml, 1 ml per well in a 6 well plate. At the same time both
siRNA (1 mM) and DharmaFECT (1:100 dilution) were separately
incubated at room temperature for 59 in Optimem, then mixed
together in a 1:1 ratio and incubated at room temperature for
additional 59. One hundred microlitres of this mixture was added
to each well (final concentration of the siRNA: 100 nM). Twenty
four hours later 1 ml of Optimem was added to each well. After
additional 24 h wells were supplemented with 2 ml of Optimem,
20% FCSi, 2,4% Dimetilsulfoxide (Sigma-Aldrich). Seventy two
hours post transfection, cells were collected, washed 16 in PBS,
resuspended in RPMI 1640, 10% FCSi and incubated for 6 h with
200 ng/ml recNefSF2.
Supporting Information
Figure S1 Nef-induced upregulation of both TNF and
IL-6 mRNAs depend on NF-kB pathway. Primary human
MDMs were pretreated for 1 h at 37uC with the highly selective
IKK/IKKb, inhibitor BMS-345541 (25 mM), then incubated for
2 h at 37uC with myr
+ wild type recNef. Cells were processed and
RT-PCR performed as described in the correspondent Materials &
Methods section. Primers used for RT-PCR were listed in Table II.
(TIF)
Figure S2 Coomassie gel showing both myr
+ recNef WT
and 4EA proteins used to stimulate cells. Two mgo fm y r
+
recNef variants were loaded on 18% SDS-PAGE. Gel was stained
using Coomassie dye. Arrows indicate wild type and 4EA myr
+recNef.
(TIF)
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